The overlaps of ES clusters and CCA subtypes indicated the potential of ES clusters in selecting personalized treatment, for example, promising IDH inhibitors (ClinicalTrials.gov identifier: NCT02073994). This evidence concerns the gene IDH1 and cholangiocarcinoma.